RCUS
Arcus Biosciences Inc (RCUS)
Healthcare • NYSE • $21.97+0.59%
- Symbol
- RCUS
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $21.97
- Daily Change
- +0.59%
- Market Cap
- $2.78B
- Trailing P/E
- N/A
- Forward P/E
- -7.08
- 52W High
- $31.74
- 52W Low
- $16.35
- Analyst Target
- $40.77
- Dividend Yield
- 0.00%
- Beta
- 0.94
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clini…
Company websiteResearch RCUS on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.